ICER Suggests Price Of $2,500-$8,300 For Biogen’s Aducanumab
Cost Watchdog Sees Insufficient Data To Show Health Benefit
Executive Summary
Given mixed Phase III results for the Alzheimer’s drug and potentially severe side effects for the once-monthly infused therapy, ICER’s recommendation came in below analyst expectations.